List view / Grid view
Genome editing technologies have given investigators the power to unlock a variety of new applications and experimental approaches. While gene knockouts have been achievable for several years, successful gene knock-ins have remained elusive due to the low efficiency of homology-directed repair (HDR).
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
The development of a Parkinson’s disease model, using hiPSC-derived neural cells, to assess alpha-synuclein pre-formed fibril-induced toxicity.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
